Activist Investing Today: Eldar on Anti-Activist Pill Evolution

The Deal
23/05/2025 23 min
Activist Investing Today: Eldar on Anti-Activist Pill Evolution

Listen "Activist Investing Today: Eldar on Anti-Activist Pill Evolution"

Descargar episodio

Episode Synopsis

When corporations install anti-activist poison pills they are less likely to implement new share buybacks and their operationally-focused capital expenditures tend to be higher, UC Berkeley School of Law professor Ofer Eldar explains.

More episodes of the podcast The Deal

Drinks With The Deal: Dechert's Thierfelder on Intensity in Practice, Management and Life 20/11/2025
Behind The Buyouts: Jefferies’ Chu on Spectrum Strategy 17/11/2025
Drinks With The Deal: UIowa's Lie on Unmasking Corporate Fraud 13/11/2025
Behind The Buyouts: JPMorgan's Berkus on Consumer M&A Rebound 10/11/2025
Activist Investing Today: Latham's Drewry, Dubofsky on Rising M&A Activism, Exxon Robo-Voting 04/11/2025
Drinks With The Deal: Proskauer's Ahn on the Lessons of a Stint In-House 29/10/2025
Activist Investing Today: Barclay's Rossman on Exxon Retail Program, Rising Campaigns 24/10/2025
Behind the Buyouts: True Beauty's Gersten, Nuñez on Scaling Emerging Brands 23/10/2025
Drinks With The Deal: Thoma Bravo's Schwab on In-House Roles 16/10/2025
Activist Investing Today: Lazard's Couvelier on Retail 'Robo-Voting,' M&A Trends 14/10/2025
© 2003-2025 ZARZA | AHEAD OF OUR TIME
privacy policy
In God we trust In God we trust
PreSales Questions? Click Here
or call our toll-free line at +1-888-5002068 Miami, Florida, USA